Astrazeneca PLCs in-depth stock price analysis indicates that the stock price has rallied 8.89% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -10.65% . Looking at the past 52 week period, the stock price is down -0.44% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Astrazeneca PLC has a negative value of -2.98 compared to overall market performance. Astrazeneca PLC (NYSE:AZN) has climbed 5.77% in the past week and advanced 3.32% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 4.91% and the outperformance has advanced to 1.47% for the last 4 weeks period.
Astrazeneca PLC (NYSE:AZN) : On Friday heightened volatility was witnessed in Astrazeneca PLC (NYSE:AZN) which led to swings in the share price. The stock opened for trading at $29.24 and hit $29.625 on the upside , eventually ending the session at $29.53, with a gain of 0.78% or 0.23 points. The heightened volatility saw the trading volume jump to 8,700,911 shares. The 52-week high of the share price is $35.04 and the company has a market cap of $74,711 million. The 52-week low of the share price is at $25.55 .
AstraZeneca plc (ADR) Last issued its quarterly earnings results on Feb 2, 2017. The company reported $1.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $1.18. The company had revenue of $5585.00 million for the quarter, compared to analysts expectations of $5625.25 million. The companys revenue was down -12.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.94 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.AstraZeneca plc (ADR) was Upgraded by Leerink Partners to Outperform on Dec 9, 2016. AstraZeneca plc (ADR) was Upgraded by Liberum to Buy on Nov 25, 2016.
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.